The Exciting journey of a vaccine
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
The use of artificial intelligence in regulatory activities – key areas and considerations
Scientific innovation is transforming the way medicines are discovered, developed, and evaluated, creating new opportunities to generate and analyze increasingly complex data and evidence. Regulatory science and regulatory systems need to evolve alongside these advances to ensure that scientific innovation can be effectively translated into innovative medicines for patients. Against this backdrop, artificial intelligence offers...
Read more
Biopharmaceutical CEO Roundtable meets in New York
05 November 2026 – The Biopharmaceutical CEO Roundtable (BCR), bringing together CEOs from leading global biopharmaceutical companies, met in New York on 3–4 November to discuss the changing global policy environment and priorities for strengthening innovation, access, and the long-term competitiveness of the sector.
Read moreWIPO’s 38th Standing Committee on Patents: Technology transfer
On 5 November 2026, IFPMA delivered a statement on technology transfer at WIPO’s 38th Standing Committee on Patents. IFPMA notes the study in document SCP/38/9 on collaboration between industry and academia. We welcome the study’s recognition that robust intellectual property frameworks, capable partners, and appropriate financing help turn research into practical applications. Furthermore, we welcome...
Read more